ARRY Mid-Q1 '19 Update


ARRY biopharma is up over 50% this year so far, as acquisition of LOXO, whose most significant clinical assets were licensed from ARRY, sparks rumors of a possible ARRY acquisition. Plus ARRY presented updated data for its lead drug candidates in colorectal cancer, continuing to show best in class results for colorectal cancer patients with the BRAF mutations. Finally, the company recently announced excellent 61% quarter over quarter revenue growth for its lead assets, which launched in the middle of 2018. At these levels we will likely keep ARRY at a low level in the fund, or take all profits.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon